ATE419870T1 - Neuer immunogener komplex - Google Patents

Neuer immunogener komplex

Info

Publication number
ATE419870T1
ATE419870T1 AT01972855T AT01972855T ATE419870T1 AT E419870 T1 ATE419870 T1 AT E419870T1 AT 01972855 T AT01972855 T AT 01972855T AT 01972855 T AT01972855 T AT 01972855T AT E419870 T1 ATE419870 T1 AT E419870T1
Authority
AT
Austria
Prior art keywords
complex
iscom
antigen
immunogenic complex
integrated
Prior art date
Application number
AT01972855T
Other languages
English (en)
Inventor
Nils Lycke
Kristian Dalsgaard
Mowat Allan Mc
Bjoern Loewenadler
Peter Kaastrup
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of ATE419870T1 publication Critical patent/ATE419870T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01972855T 2000-09-29 2001-10-01 Neuer immunogener komplex ATE419870T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0003538A SE0003538D0 (sv) 2000-09-29 2000-09-29 New immunogenic complex

Publications (1)

Publication Number Publication Date
ATE419870T1 true ATE419870T1 (de) 2009-01-15

Family

ID=20281259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972855T ATE419870T1 (de) 2000-09-29 2001-10-01 Neuer immunogener komplex

Country Status (8)

Country Link
US (1) US7452982B2 (de)
EP (1) EP1320381B1 (de)
AT (1) ATE419870T1 (de)
AU (2) AU2001292493B2 (de)
CA (1) CA2423983C (de)
DE (1) DE60137347D1 (de)
SE (1) SE0003538D0 (de)
WO (1) WO2002026255A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2011507511A (ja) * 2007-12-19 2011-03-10 ミヴァック ディベロップメント アクティエボラグ 自己免疫疾患及びアレルギー性疾患の治療用組成物及び方法
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
WO2016022028A1 (en) 2014-08-08 2016-02-11 Universiteit Utrecht Holding B.V. Mutant porcine epizootic diarrhea virus for use in a vaccine
US20180161433A1 (en) * 2017-03-22 2018-06-14 Timothy Andrew Erickson Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN110904127A (zh) 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2021230804A1 (en) 2020-05-15 2021-11-18 Transmed Gothenburg Ab Fusion protein with immunoenhancing activity
WO2022019769A1 (en) 2020-07-23 2022-01-27 Universiteit Utrecht Holding B.V. Bordetella outer membrane vesicles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
AU675234B2 (en) * 1992-06-26 1997-01-30 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet

Also Published As

Publication number Publication date
EP1320381B1 (de) 2009-01-07
AU9249301A (en) 2002-04-08
CA2423983A1 (en) 2002-04-04
CA2423983C (en) 2012-06-05
SE0003538D0 (sv) 2000-09-29
DE60137347D1 (de) 2009-02-26
US20040052815A1 (en) 2004-03-18
WO2002026255A1 (en) 2002-04-04
EP1320381A1 (de) 2003-06-25
US7452982B2 (en) 2008-11-18
AU2001292493B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
ATE419870T1 (de) Neuer immunogener komplex
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
TR200102739T2 (tr) Aşı
CR8231A (es) Anticuerpos rg1 y uso de los mismos
BR0208456A (pt) Métodos para cultura de circovìrus
MY137202A (en) System and method for a unified composition engine in a graphics processing system
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
TR201908551T4 (tr) Yakıt bileşimleri.
BRPI0511026A (pt) uso de um los neisserial, e, composição
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
ATE329617T1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
TW200515916A (en) Chimeric antigens for breaking host tolerance to foreign antigens
BR9806764A (pt) Moléculas mutantes ctla4 solúveis e usos das mesmas.
DK2054431T3 (da) Konformere af bakterielle adhæsiner
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
MY141459A (en) Recombinant anti-idiotypic antibodies
GB0401239D0 (en) Adjuvant compositions
EP1594533A4 (de) Antikörper-vakzine-konjugate und ihre verwendungen
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
WO2000044775A3 (en) Identification of broadly reactive hla restricted t cell epitopes
BR0212289A (pt) Anticorpos contra caspase-8, preparação e uso do mesmo
BR0104357A (pt) Uso de receptores de toxina gbs ou fragmentos imunogênicos dela para prevenir uma condição patoangiogênica em um mamìfero
AU2001294565A1 (en) In vitro assay for measuring the immunogenicity of a vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties